Producers of biosimilars - how to assess products, developments, and revenue prospects What does the future hold for makers of biosimilar drugs? Visiongain's updated report shows you those companies' prospects to 2023. There you see results, trends, opportunities, and revenue predictions.
Our study analyses 25 leading developers, producers and marketers of biosimilars, also with discussion of other companies. There you find information on established and rising organisations. Discover their sales potentials.
That investigation is for everyone interested in the future of biopharmaceuticals. See now how you can benefit.
Forecasts and other data to help you stay ahead in knowledge of those biological drugs In that report you find analytical profiles of top companies worldwide. There you analyse historical data, R&D, market shares, revenue forecasts, and growth rates. See qualitative analysis too for those biologics. You also gain 97 charts, 44 tables and an interview. That work lets you assess the most lucrative parts of the industry for biosimilar drugs. Get revenue forecasts to 2023 for eight of the companies. See there how you can benefit your research, analyses, and decisions, also saving time.
Find where money lies for those protein-based medicines. The following sections explain what you get in that new analysis.
Companies based in regions with developed pharma industries
First, our study gives you discussions, financial analyses, and commercial outlooks for six biosimilar drug producers among the leading drug-producing countries:
Sandoz
Teva
Hospira
Stada Arzneimittel
Medice Arzneimittel Pütter
JCR Pharmaceuticals.
You see possibilities there for business performance. Discover what the future holds for those companies, including revenue predictions to 2023 for top firms. Hear too about other companies, including Actavis, Mylan, Pfizer, Boehringer Ingelheim, Mochida, and Nichi-Iko.
China - outlooks for leading biosimilar drug manufacturers
Next, our report analyses five Chinese biosimilar specialists:
3SBio
Beijing SL Pharmaceutical
GeneScience Pharmaceuticals
Shanghai Fosun
Tonghua Dongbao.
Many opportunities remain, with high, expanding revenues possible from 2013. See where best potentials exist.
India - prospects for leading players
You also discover outlooks for six Indian biosimilar specialists:
Biocon
Dr. Reddy's Laboratories
Intas Biopharmaceuticals
Reliance Life Sciences
Wockhardt
Zydus Cadila.
You also hear about activities of Ranbaxy, Cipla, and Lupin. Our report shows you how companies seize opportunities and expand their revenues.
Latin America - analysis of leading biological drug firms
Our new work also assesses four Latin American biosimilar drug producers:
Probiomed
Biosidus
Amega Biotech
Aché.
You find revenue data, trends, and opportunities there, seeing activities, product ranges, and prospects.
Producers from Central and Eastern Europe (CEE), Russian Federation, and South Korea You also discover outlooks and activities of companies based in other developing countries:
Bioton
Pharmstandard
LG Life Sciences
Dong-A Pharmaceutical.
Developing and developed national markets will prove important for biosimilar drug sales from 2013 to 2023, our analyses show. Discover what the future holds.
Revenue prediction for the overall biosimilars market and its submarkets
Our report also forecasts revenues to 2023 for the world biosimilars industry and seven main segments:
EPO
Insulin
Filgrastim
Somatropin
Interferons
FSH
Monoclonal antibodies (mAbs).
There you see overall world revenues in 2017 reaching $8.8bn. Our analyses reveal high sales growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. Ways Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023 helps you In particular, our new report gives you the following knowledge:
Profiles of 25 leading companies - assess product ranges, strategies, and sales results, also gaining revenue forecasts to 2023 for 8 organisations
Competition and opportunities - explore what affects the biosimilars market, finding what shapes its future, esp. prospects for sustaining and developing business
Revenues to 2023 for that industry at world level, with forecasting of 7 submarkets - discover overall outlooks for commercial success.
Analysis found nowhere else - discover the future of those biologics
Our work gives independent analysis. There you receive competitive intelligence found only in our report. You discover where prospects are most rewarding.
With that investigation you're less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Also find how you could save time and get recognition for understanding, increasing your influence.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
Additional Information 3.4.4.2 Stada: Biosimilar Revenue Forecast, 2013-2023
Between 2012 and 2017, Stada’s biosimilar revenue will grow with a CAGR of 17.1%, growing
from $48m to $106m, visiongain forecasts. This growth will be dependent on the increased uptake
of Silapo in markets such as Germany. Growth will be restrained by increased competition in this
marketplace, driving down prices, as well as decreased demand for EPO products. Beyond the
middle of the forecast period, growth for Stada’s biosimilar revenue will depend upon the launch of
new biosimilar products, in particular its two monoclonal antibodies, which are due to be launched
in 2017. Its biosimilar rituximab is unlikely to be the first launched in the EU, however, and will
therefore compete with other products upon launch. By 2023, Stada’s biosimilar revenue will have
grown to $361m (Table 3.15 and Figure 3.9). During the forecast period, Stada’s biosimilars
market share will fall by almost half, from 2.4% to 1.3% (Figure 3.10).
Companies Listed
3SBio (Shenyang Sunshine Pharmaceutical) Abbott Laboratories Aché Actavis Affitech Amega Biotech Amgen Amicus Therapeutics Anglo Gulf (part of MJ Group) Apotex Aprogen ASKA Pharmaceutical AstraZeneca Avesthagen AxiCorp AzkoNobel Baxter International Bayer Beijing Four Rings Bio-pharmaceutical Beijing SL Pharmaceutical Bigpearl Trading (part of Pharmstandard) Bioceuticals Arzneimittel (part of Stada) Biocon Biogen Idec BioGeneriX (part of Teva) BioMab Biomed (part of Pharmstandard) Bionovis Biopartners (part of Bioton) Biopharmaceuticals and Herbal Medicines Bureau [South Korea] Biosidus (part of Sidus Pharmaceutical Group) Bioton Biovel Life Sciences (part of Ranbaxy) Blau Farmacêutica Boehringer Ingelheim Bristol-Myers Squibb Cell Pharm (part of Stada) Celltrion Central Drugs Standard Control Organization (CDSCO) [India] Chemo Group China National Pharmaceutical Group (Sinopharm) CinnaGen Cipla CJ Corporation Clinigene International (part of Biocon) CoGenesys (part of Teva) Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico] Committee for Medicinal Products for Human Use (CHMP) [EU] CT Arzneimittel (part of Teva) CureTech (part of Teva) Daiichi Sankyo Dainippon Sumitomo Pharma DaVita Department of Biotechnology (DBT) [India] Diapin Therapeutics DM Bio Dong-A Pharmaceutical Dr. Reddy's Laboratories Drug Controller General of India (DCGI) Eden Biodesign (part of Watson) Egis Pharmaceuticals Eli Lilly Emcure Pharmaceuticals EMS Epitomics European Medicines Agency (EMA) Ferring Pharmaceuticals Finox Food and Drug Administration (FDA), [US] Fosun International Fresenius Medical Care Fuji Pharma Fujifilm Funda??o Ezequiel Dias (Funed) [Brazil] Gan & Lee Pharmaceutical Gedeon Richter Genentech (part of Roche) GeneScience Pharmaceuticals Gennova Biopharmaceuticals (part of Emcure Pharmaceuticals) Genzyme (part of Sanofi) German Remedies (part of Zydus Cadila) Germonta Holdings (part of Bioton) Green Cross Corporation GSK Hangzhou Jiuyuan Gene Engineering Hanwha Chemical Haselmeier Hefei-SciGen-Bioton Biopharmaceutical Company Hemofarm (part of Stada) Hexal (part of Novartis) Hikma Pharmaceuticals Hospira Hospira Japan (part of Hospira) Hualida Biotech Human Genome Sciences (part of GSK) Hypermarcas IATRICa iBio Insmed Intas Biopharmaceuticals (part of Intas Pharmaceuticals) Intas Pharmaceuticals International Biotech Center (IBC) Generium Isotechnika Pharma Isu Abxis Itero Biopharmaceuticals JCR Pharmaceuticals Johnson & Johnson (J&J) Kissei Pharmaceutical Korea Food and Drug Administration (KFDA) Kwizda Pharma Kyowa Hakko Kirin Laboratórios Biosintética (part of Aché) Landsteiner Scientific Lekko (part of Pharmstandard) LG LG Chem Investment (part of LG) LG Life Sciences Lonza Lupin Pharmaceuticals MabPharm Marvel Life Sciences (part of MJ Group) Masterlek (part of Pharmstandard) Medice Arzneimittel Pütter MedImmune (part of AstraZeneca) Meiji Seika Pharma Merck BioVentures Merck & Co. Merck KGaA Mindar Holdings (part of Bioton) Ministry of Health [Brazil] Ministry of Health and Family Welfare [India] Ministry of Health, Labor and Welfare (MHLW) [Japan] Ministry of Science and Technology [India] MJ Biopharm (part of MJ Group) MJ Bioton Life Sciences MJ Group Mochida Pharmaceutical Mylan NeuClone Nichi-Iko Pharmaceutical Nippon Kayaku Nipro Pharma Nobel Ilac Norbitec Nordmark Arzneimittel Novartis Novo Nordisk Organon (part of Merck & Co.) Owen Mumford Parexel International Pfenex Pfizer Pharmaceuticals and Medical Devices Agency (PMDA) [Japan] Pharmapark (part of Pharmstandard) Pharmstandard Pharmstandard-Biolek (part of Pharmstandard) PlantForm Pliva (part of Teva) Polpharma Polpharma Biologics (part of Polpharma) Probiomed Prolong Pharmaceuticals Proquifin Qilu Pharmaceutical Quintiles Ranbaxy Laboratories ratiopharm (part of Teva) Reliance GeneMedix (part of Reliance Life Sciences) Reliance Group Reliance Life Sciences (part of Reliance Group) Rentschler Biotechnologie Roche Royal DSM Safety Syringes Samsung Samsung Bioepis Samsung BioLogics Sandoz (part of Novartis) Sanofi sanofi-aventis Nichi-Iko Savient Pharmaceuticals (part of Ferring) Schering-Plough (part of Merck & Co.) Schnell Biopharmaceuticals SciGen Shandong Kexing Bioproducts Shanghai Celgen Bio-Pharmaceutical Shanghai Chemo Wanbang Biopharma Shanghai CP Goujian Pharmaceutical Shanghai Fosun Pharmaceutical Shanghai Henlius Biotech Shantha Biotechnics (part of Sanofi) Sicor Biotech (part of Teva) Sidus Pharmaceutical Group Silanes Stada Arzneimittel State Food and Drug Administration (SFDA) [China] State's Employees′ Social Security and Social Services Institute (ISSSTE) [Mexico] Sundiro Pharma Syngene (part of Biocon) Teva Pharmaceutical Industries Teva-Kowa Pharma (part of Teva) The United Laboratories Therapeutic Goods Administration (TGA) [Australia] TL Biopharmaceutical Tonghua Dongbao Uni?o Química University of Michigan Wanbang Biopharmaceuticals (part of Shanghai Fosun Pharmaceuticals) Watson Pharmaceuticals Wockhardt World Health Organization (WHO) Xiamen Amoytop Biotech Ypsomed Zao Indar Zenotech Laboratories Zuventus Healthcare (part of Emcure Pharmaceuticals) Zydus Cadila